Letter to the Editor: statistics and clinical perception of patients’ reported outcomes for palbociclib and abemaciclib: a sliding doors story-Reference-Cited by-同舟云学术

Letter to the Editor: statistics and clinical perception of patients’ reported outcomes for palbociclib and abemaciclib: a sliding doors story

Published:2023-06 Issue:6 Volume:12 Page:
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:J. Comp. Eff. Res.

Author:

Gebbia Vittorio¹²^ORCID,Valerio Maria Rosaria³^ORCID,Martorana Federica⁴⁵^ORCID,Sanò Maria Vita⁴,Vigneri Paolo⁵^ORCID

Affiliation:

1. Kore University of Enna, Enna, 94100, Italy

2. Medical Oncology Units, La Maddalena Clinic for Cancer, Palermo, 90100, Italy

3. Medical Oncology Unit, Policlinico P. Giaccone, University of Palermo, Palermo, 90100, Italy

4. Medical Oncology Unit, Istituto Clinico Humanitas, Catania, 95100Italy

5. Department of Clinical & Experimental Medicine, University of Catania, Catania - Italy, & Center of Experimental Oncology & Hematology AOU, Policlinico ‘G. Rodolico – San Marco’, Catania, 95100, Italy

Publisher

Becaris Publishing Limited

Subject

Health Policy

Link

https://becarispublishing.com/doi/pdf/10.57264/cer-2022-0212

Reference13 articles.

1. Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points

2. overall survival with palbociclib and fulvestrant in advanced breast cancer;Turner NC;N. Engl. J. Med.,2018

3. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial;Sledge GW;JAMA Oncol.,2020

4. Hayward Medical Communications. What is indirect comparison? www.quantics.co.uk/wp-content/uploads/2017/08/What-is-indirect-comparison.pdf

5. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, Phase III randomised controlled trial;Cristofanilli M;Lancet Oncol.,2016